AORT - Artivion, Inc.
Artivion NYSE: AORT reported second-quarter 2026 revenue of $125.8 million, up 9% year over year on a constant-currency basis, as growth in stent grafts and On-X heart valves offset modest declines in BioGlue. Adjusted EBITDA rose about 7% to $26.4 million, while adjusted EBITDA margin declined roughly 90 basis points to 21% amid higher research and development spending and costs related to the Endospan acquisition.
Artivion, Inc. (AORT) Q2 2026 Earnings Call Transcript
Artivion (AORT) came out with quarterly earnings of $0.13 per share, in line with the Zacks Consensus Estimate . This compares to earnings of $0.24 per share a year ago.
Second Quarter & Recent Business Highlights: Achieved revenue of $125.8 million in the second quarter of 2026 versus $113.0 million in the second quarter of 2025, an increase of 11% on a GAAP basis and 9% on a non-GAAP constant currency basis Net loss for the second quarter of 2026 was $(13.5) million, or $(0.28) per fully diluted share, and non-GAAP net income was $6.3 million, or $0.13 per fully diluted share Adjusted EBITDA increased 7% to $26.4 million in the second quarter of 2026 compared to $24.8 million in the second quarter of 2025 Announced U.S. FDA PMA Approval of the AMDS Hybrid Prosthesis Completed acquisition of Endospan Ltd. ATLANTA, Aug. 6, 2026 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced financial results for the second quarter ended June 30, 2026.
ATLANTA, July 28, 2026 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate in two upcoming investor conferences. Artivion's management team will present at the upcoming Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026 at the InterContinental Boston Hotel.
ATLANTA, July 23, 2026 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that second quarter 2026 financial results will be released on Thursday, August 6, 2026, after the market closes. On that day, the Company will hold a teleconference call and live webcast at 4:30 p.m.
Fifth Third Bancorp lifted its stake in Artivion, Inc. (NYSE: AORT) by 58,029.7% in the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 123,235 shares of the company's stock after acquiring an additional 123,023 shares during the period. Fifth Third
AORT's FDA approval for AMDS removes a key hospital adoption hurdle and opens access to an estimated $150 million annual U.S. market.
Artivion benefits from FDA premarket approval of AMDS, removing adoption barriers and unlocking a $150M U.S. TAM in acute aortic dissection. AMDS's clinical data shows reduced mortality and major adverse events, with the elimination of DANE tears and durable benefit, supporting rapid, adoption-driven commercial scaling. AORT demonstrates double-digit revenue growth, margin expansion, and a shift to GAAP profitability, with EBITDA up 26% and gross margins nearing 65%.
ATLANTA, June 29, 2026 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that the U.S. Food and Drug Administration (FDA) has approved the premarket approval application (PMA) for the AMDS Hybrid Prosthesis ("AMDS"). The approval covers acute Debakey Type I aortic dissections with either clinical or radiographic malperfusion, which the Company estimates to be approximately 60% of all Debakey Type I aortic dissections.
ATLANTA, June 10, 2026 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it will participate at the upcoming 2026 Truist Securities MedTech Conference on Tuesday, June 16, 2026, at the Boston Harbor Hotel. The Company's fireside chat is scheduled to begin at 1:00 p.m.
Endospan, a pioneer in endovascular solutions for complex aortic pathologies, today announced that Artivion, Inc. (NYSE: AORT) has closed the transaction to ac
HERZLIYA, Israel--(BUSINESS WIRE)-- #aortaEd--Endospan, a pioneer in endovascular solutions for complex aortic pathologies, today announced that Artivion, Inc. (NYSE: AORT) has closed the transaction to acquire the company. This strategic milestone follows the April 2026 U.S. Food and Drug Administration (FDA) PMA approval of the NEXUS® Aortic Arch System, the first off-the-shelf endovascular solution designed to treat aortic arch disease, including chronic aortic dissections, in patients at high risk for.
ATLANTA, May 18, 2026 Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it has completed the acquisition of its long-standing partner Endospan Ltd. ("Endospan"), a pioneer in the endovascular repair of aortic arch disease and developer of the NEXUS® Aortic Arch System.
Artivion delivers advanced cardiovascular and vascular solutions to healthcare providers worldwide through its proprietary medical devices.
MILWAUKEE, May 11, 2026 /PRNewswire/ -- Ademi LLP is investigating possible securities fraud claims against Artivion (NYSE: AORT). The investigation results from inaccurate statements Artivion may have made regarding its financial statements, business operations and prospects.
Artivion, Inc. (AORT) Q1 2026 Earnings Call Transcript
Artivion NYSE: AORT executives said the company delivered double-digit revenue and adjusted EBITDA growth in the first quarter of 2026, while also lowering its full-year revenue outlook due primarily to softer stent graft trends and timing around U.S. AMDS account stocking.
Artivion (AORT) came out with quarterly earnings of $0.08 per share, beating the Zacks Consensus Estimate of $0.06 per share. This compares to earnings of $0.06 per share a year ago.
First Quarter & Recent Business Highlights: Achieved revenue of $116.3 million in the first quarter of 2026 versus $99.0 million in the first quarter of 2025, an increase of 18% on a GAAP basis and 12% on a non-GAAP constant currency basis Net income for the first quarter of 2026 was $1.4 million, or $0.03 per fully diluted share, and non-GAAP net income was $4.2 million, or $0.08 per fully diluted share Adjusted EBITDA increased 26% to $22.1 million in the first quarter of 2026 compared to $17.5 million in the first quarter of 2025 Announced U.S. FDA PMA Approval of the NEXUS Aortic Arch System for the treatment of aortic arch disease, including chronic aortic dissections Exercised option to acquire Endospan for an upfront purchase price of $135 million, net of previously extended loans ATLANTA, May 7, 2026 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced financial results for the first quarter ended March 31, 2026. "In the first quarter of 2026, we achieved 12% constant currency revenue growth and 26% adjusted EBITDA growth, reflecting continued execution of our strategy to deliver long-term, profitable performance with an expanding and clinically differentiated product portfolio.